Evercore ISI Group Maintains Outperform on Cabaletta Bio, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Gavin Clark-Gartner maintains an Outperform rating on Cabaletta Bio (NASDAQ:CABA) but lowers the price target from $25 to $15.

August 12, 2024 | 1:57 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Evercore ISI Group maintains an Outperform rating on Cabaletta Bio but lowers the price target from $25 to $15.
The Outperform rating suggests continued confidence in Cabaletta Bio's performance, but the lowered price target indicates a more conservative outlook on its short-term valuation. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100